Voya Investment Management LLC cut its holdings in shares of Stryker Corporation (NYSE:SYK – Free Report) by 6.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 52,532 shares of the medical technology company’s stock after selling 3,483 shares during the quarter. Voya Investment Management LLC’s holdings in Stryker were worth $14,467,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. International Assets Investment Management LLC lifted its holdings in Stryker by 1,432.8% during the 3rd quarter. International Assets Investment Management LLC now owns 25,000 shares of the medical technology company’s stock worth $6,885,000 after buying an additional 23,369 shares during the last quarter. Amundi raised its position in shares of Stryker by 18.3% during the 2nd quarter. Amundi now owns 1,246,353 shares of the medical technology company’s stock valued at $392,402,000 after acquiring an additional 192,447 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Stryker by 8.2% during the second quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company’s stock worth $270,642,000 after purchasing an additional 65,333 shares during the last quarter. Veritas Asset Management LLP bought a new position in Stryker during the second quarter worth $168,057,000. Finally, Bank of America Corp DE acquired a new position in Stryker in the second quarter worth $1,404,284,000. 77.09% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Stryker
In related news, Director Ronda Stryker sold 550,000 shares of the firm’s stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $325.32, for a total value of $178,926,000.00. Following the sale, the director directly owned 1,701,375 shares in the company, valued at $553,491,315. This trade represents a 24.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.60% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on SYK shares. Raymond James Financial reaffirmed an “outperform” rating and set a $323.00 price objective (down from $370.00) on shares of Stryker in a research report on Friday, October 30th. Citigroup restated a “market outperform” rating on shares of Stryker in a research note on Friday, October 30th. JPMorgan Chase & Co. lowered their target price on Stryker from $350.00 to $340.00 and set an “overweight” rating for the company in a report on Friday, October 30th. Johnson Rice cut Stryker to a “hold” rating in a research report on Friday, October 30th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Stryker in a report on Thursday, October 29th. Twenty-one research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $343.77.
Read Our Latest Stock Analysis on Stryker
Stryker Trading Down 1.0%
Shares of NYSE:SYK opened at $309.91 on Friday. The company has a quick ratio of 1.30, a current ratio of 2.18 and a debt-to-equity ratio of 0.60. The company’s 50-day moving average price is $295.66 and its 200 day moving average price is $321.39. The company has a market cap of $117.98 billion, a PE ratio of 33.00, a P/E/G ratio of 2.13 and a beta of 0.78. Stryker Corporation has a fifty-two week low of $267.00 and a fifty-two week high of $389.33.
Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing the consensus estimate of $3.55 by ($0.03). The firm had revenue of $6.52 billion during the quarter, compared to analyst estimates of $6.62 billion. Stryker had a net margin of 13.78% and a return on equity of 23.74%. Stryker’s revenue for the quarter was up 7.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.19 EPS. Sell-side analysts anticipate that Stryker Corporation will post 14.85 earnings per share for the current year.
About Stryker
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
Featured Articles
- Five stocks we like better than Stryker
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
